Canada markets open in 1 hour 48 minutes
  • S&P/TSX

    20,714.48
    +13.98 (+0.07%)
     
  • S&P 500

    4,070.56
    +10.13 (+0.25%)
     
  • DOW

    33,978.08
    +28.68 (+0.08%)
     
  • CAD/USD

    0.7504
    -0.0011 (-0.15%)
     
  • CRUDE OIL

    79.69
    +0.01 (+0.01%)
     
  • BTC-CAD

    30,809.13
    -562.26 (-1.79%)
     
  • CMC Crypto 200

    523.02
    +6.01 (+1.16%)
     
  • GOLD FUTURES

    1,941.70
    -3.90 (-0.20%)
     
  • RUSSELL 2000

    1,911.46
    +8.40 (+0.44%)
     
  • 10-Yr Bond

    3.5180
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,077.00
    -145.25 (-1.19%)
     
  • VOLATILITY

    19.99
    +1.26 (+6.73%)
     
  • FTSE

    7,768.85
    +3.70 (+0.05%)
     
  • NIKKEI 225

    27,433.40
    +50.84 (+0.19%)
     
  • CAD/EUR

    0.6885
    -0.0026 (-0.38%)
     

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders seem bullish, own 59% and have been buying more recently

If you want to know who really controls Greenwich LifeSciences, Inc. (NASDAQ:GLSI), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are individual insiders with 59% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Notably, insiders have bought shares recently. This might indicate that they expect share prices to rise in the near future.

In the chart below, we zoom in on the different ownership groups of Greenwich LifeSciences.

Check out our latest analysis for Greenwich LifeSciences

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Greenwich LifeSciences?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

As you can see, institutional investors have a fair amount of stake in Greenwich LifeSciences. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Greenwich LifeSciences' historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Greenwich LifeSciences is not owned by hedge funds. The company's CEO Snehal Patel is the largest shareholder with 41% of shares outstanding. In comparison, the second and third largest shareholders hold about 6.6% and 4.8% of the stock. Interestingly, the third-largest shareholder, David McWilliams is also a Chairman of the Board, again, indicating strong insider ownership amongst the company's top shareholders.

After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.

Insider Ownership Of Greenwich LifeSciences

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own the majority of Greenwich LifeSciences, Inc.. This means they can collectively make decisions for the company. So they have a US$74m stake in this US$127m business. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

General Public Ownership

With a 19% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Greenwich LifeSciences. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Company Ownership

Our data indicates that Private Companies hold 13%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For example, we've discovered 3 warning signs for Greenwich LifeSciences (2 are a bit unpleasant!) that you should be aware of before investing here.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here